Navigation Links
Avantium Appoints Gunnar Staaf as CEO Pharma
Date:12/16/2009

AMSTERDAM, December 16 /PRNewswire/ -- Today, Avantium announced the appointment of Gunnar Staaf as Chief Executive Officer of its pharmaceutical business. Gunnar Staaf previously worked at Serentis Ltd, Astellas Pharma, Novartis and Eli Lilly & Company, in a range of commercial and executive positions. The appointment is an important step in Avantium's plan to spin-out its pharmaceutical business. The company intends to create a stand-alone pharmaceutical company based on its offering of proprietary crystallization services and systems to customers in the pharmaceutical and biotechnology sector as well as the development of improved forms of existing drugs. After the spin-out of its pharmaceutical business, Avantium will focus on its cleantech and chemicals activities, including its Furanics bioplastics and biofuels program and offering of high-throughput catalysis services & systems.

Tom van Aken, CEO of Avantium, commented: "With his background in the pharmaceutical industry and wealth of commercial experience, Gunnar is a tremendous addition to our company. The appointment of Gunnar is an important step towards a focused pharmaceutical company. Under Gunnar's leadership we believe that our Pharma business will accelerate the development of improved drug forms, and will further strengthen our position as a leading solid-state research services & systems provider."

Upon his appointment Gunnar Staaf commented: "I am pleased to join Avantium at this exciting stage. The company has an excellent technological position and expertise in crystallization research and is a leading provider of services & systems in this area. The technology forms a strong basis for the development of novel forms and formulations of existing drugs. I am convinced that we have all the ingredients to become a dedicated and successful pharmaceutical company."

About Avantium

Avantium is a leading technology company in the area of advanced high-throughput R&D operating in the energy, chemicals and pharmaceutical industries. The company develops products and processes in the area of biofuels, bio-based chemicals and novel crystal forms of existing drugs by applying its proprietary, high-throughput R&D technology.

Avantium has demonstrated the potential of this technology by providing R&D services and tools to more than 70 companies worldwide. Avantium's customer base includes many of the world's largest energy, chemicals and pharmaceutical companies, such as BP, Shell, Sasol, Pfizer and GSK. Avantium has more than 100 employees; its offices and head quarters are based in Amsterdam, The Netherlands.

For more information

Please visit our website http://www.avantium.com

SOURCE Avantium


'/>"/>
SOURCE Avantium
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors
2. Millstone Medical Outsourcing Appoints New Leadership of Memphis Facility
3. Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer
4. Jazz Pharmaceuticals Appoints Kathryn Falberg as Chief Financial Officer
5. Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer
6. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
7. Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors
8. Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing
9. NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates
10. Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors
11. Company Appoints New SVP, Marketing for PBM Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , Mar. 24, 2017 Research ... Management in the U.S.: Consumer Strategies" report to their ... ... how adults approach and treat their physical pain, emphasizing consumer ... distinct groups: pain sufferers and adults who have selected illnesses/conditions ...
(Date:3/24/2017)... FinancialBuzz.com News Commentary  ... According to new data ... research, the legal cannabis market is projected to continue to ... signals from the current presidential administration. The report created by ... drivers of growth in this industry are the passage and ...
(Date:3/24/2017)... , March 24, 2017 A ReportsnReports.com ... has been growing rapidly as the global sales of Adcetris and ... growth in the antibody drug conjugates market is driven by large ... cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer ... for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred Peru retreat ... This sacred and spiritual journey during the Summer Solstice will also be her ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. ... the Administrative Record, The majority of cases litigated under ERISA involve claims for ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower ... upgrading their training and leads programs. , In February, 2017, Empower Brokerage introduced ... agents, Performance Partners is designed to teach how to maximize their sales efforts, ...
(Date:3/24/2017)... ... ... “Vintage and Harvest A Cultivation of Christian Love” is the creation of published author, ... his wife, Anna Marie. He and his wife are the proud parents of four ... of “Shadow and Substance.” , “Love, the agape kind, is seen as more than ...
(Date:3/23/2017)... ... 23, 2017 , ... A recent report from the National Council on Teacher ... NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at 221 ... the U.S. It argues that this higher bar should be set by states, by ...
Breaking Medicine News(10 mins):